Sumifilam phase 3. , Canada and Australia.

Sumifilam phase 3. Barry. , Canada and Australia. The trial that failed is over, and the company has also shut down a second ongoing Phase 3 trial because of this negative data. 3 days ago · The Austin, Texas-based biotech revealed that simufilam failed its first phase 3 test in mild-to-moderate Alzheimer's and a second study has now been halted, leading to an 84% drop in its Nov 26, 2024 · As a result of these findings, the company has decided to discontinue its second phase 3 study of simufilam, ReFocus-ALZ (NCT05026177). Mar 25, 2025 · “Cassava will discontinue all efforts to develop simufilam for Alzheimer’s disease and we expect to phase out the program by the end of Q2 2025,” continued Mr. Nov 25, 2024 · ReThink-ALZ (NCT04994483) is a Phase 3 trial designed to evaluate the safety and efficacy of simufilam compared to a placebo in a multi-center, double-blinded, placebo-controlled, randomized parallel group study involving over 75 clinical trial sites in the U. S. The primary objective is to assess simufilam’s effect on the co-primary endpoints of ADAS-Cog12 and the ADCS-ADL, baseline to the end of double-blind treatment (Week 52). . Apr 4, 2025 · Cassava Sciences will discontinue developing simufilam for mild to moderate Alzheimer’s disease by the end of the second quarter of this year after the experimental treatment failed to meet key Phase 3 trial goals for improving cognition and daily function. Nov 25, 2024 · On November 25th, Cassava Sciences announced their experimental Alzheimer’s drug simufilam failed to slow cognitive or functional decline in its 52-week Phase 3 trial. olue jrtjfwvm byjh rqdgc armhkm izouo cuyqkfd jeivpp euhluxp mjga